Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower

MT Newswires Live12-11

Immix Biopharma (IMMX) said Tuesday that updated data for its drug NXC-201 showed a 94% overall response rate in patients with AL amyloidosis.

The drug had a complete response rate of 75% in the phase 1b/2 Nexicart-1 study, according to the company.

One patient maintained a complete response for 31.5 months, with ongoing remission as of Dec. 9, Immix added.

Shares of Immix were down 7.4% in recent trading.

Price: 2.25, Change: -0.29, Percent Change: -11.42

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490010284?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 00:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490010284","market":"hk","top_or_hot":-1,"title":"Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower","media":"MT Newswires Live","content":"<html><body><p> Immix Biopharma (IMMX) said Tuesday that updated data for its drug NXC-201 showed a 94% overall response rate in patients with AL amyloidosis.</p><p>The drug had a complete response rate of 75% in the phase 1b/2 Nexicart-1 study, according to the company.</p><p>One patient maintained a complete response for 31.5 months, with ongoing remission as of Dec. 9, Immix added.</p><p>Shares of Immix were down 7.4% in recent trading.</p><p>Price: 2.25, Change: -0.29, Percent Change: -11.42</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 00:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immix Biopharma (IMMX) said Tuesday that updated data for its drug NXC-201 showed a 94% overall response rate in patients with AL amyloidosis.The drug had a complete response rate of 75% in the phase ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490010284","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490010284","pubTimestamp":1733846988,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immix Biopharma  said Tuesday that updated data for its drug NXC-201 showed a 94% overall response rate in patients with AL amyloidosis.The drug had a complete response rate of 75% in the phase 1b/2 Nexicart-1 study, according to the company.One patient maintained a complete response for 31.5 months, with ongoing remission as of Dec. 9, Immix added.Shares of Immix were down 7.4% in recent trading.Price: 2.25, Change: -0.29, Percent Change: -11.42","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMMX":"Immix Biopharma, Inc"},"translate_title":"Immix Biopharma更新了罕见病候选药物的临床数据；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMMX":0.9},"content_text":"Immix Biopharma (IMMX) said Tuesday that updated data for its drug NXC-201 showed a 94% overall response rate in patients with AL amyloidosis.The drug had a complete response rate of 75% in the phase 1b/2 Nexicart-1 study, according to the company.One patient maintained a complete response for 31.5 months, with ongoing remission as of Dec. 9, Immix added.Shares of Immix were down 7.4% in recent trading.Price: 2.25, Change: -0.29, Percent Change: -11.42","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490010284"}